What Алвента treats: main uses and benefits

The medication is commonly used across therapeutic domains involving emotional distress and related physical symptoms. It is primarily applied for the management of Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), Social Anxiety Disorder (SAD), and Panic Disorder. It is also relevant in clinical settings for specific types of chronic discomfort.

In clinical scenarios, the medication helps address symptom clusters that may become intense or disruptive, such as profound anhedonia (loss of pleasure), persistent fatigue, and pervasive, uncontrollable worry. It is often used during phases when symptoms become more noticeable, offering supportive relief that helps patients cope more steadily with difficult episodes.

“This medication is considered relevant across conditions where symptomatic relief is needed to support emotional stability and general comfort.”

The overall therapeutic benefit contributes to easing the symptom load and supports general well-being during symptomatic phases in individuals with recurrent or chronic patterns of emotional distress. This supportive management is also relevant for easing symptoms that create noticeable physiological strain, such as chronic neuropathic pain and hot flashes (vasomotor symptoms) in relevant patient groups.

Quick Fact: Symptomatic Relief Domains
Mood	Helps with managing symptoms related to low mood and anhedonia.
Anxiety	Assists with managing excessive worry and may help ease the discomfort of panic attacks.
Somatic	Applied for symptomatic relief of certain chronic nerve pain and hot flashes.

Regulatory References

1. NIH MedlinePlus Drug Information on Venlafaxine

Official Eligibility Rules for Алвента (Venlafaxine)

The official regulatory documentation strictly defines the populations who can and cannot use Алвента, based on contraindications, age restrictions, and conditional use requirements.

Contraindications

• Hypersensitivity: The medicine is formally contraindicated in patients with a known allergy to venlafaxine or any of its excipients.
• MAOI Use: Use is prohibited when concurrently taking a psychiatric Monoamine Oxidase Inhibitor (MAOI). A mandated 14-day washout period must be observed before starting venlafaxine after discontinuing an MAOI.

Conditional Eligibility

Population Group	Eligibility Status (Regulatory)
Age Restriction	Approved use is strictly limited to adults aged 18 years and older. Use in children and adolescents is not approved or not recommended by regulators.
Renal/Hepatic Impairment	Eligible for use, but only with a required dose reduction (up to 50% or more), as mandated by the label, depending on the severity of the impairment.
Pregnancy	Permissible only if clearly needed. Third-trimester use is associated with the risk of poor neonatal adaptation syndrome in the newborn.
Lactation	Requires a decision to either discontinue the drug or discontinue nursing, as mandated by regulatory guidelines.
Comorbidities	Use must be exercised with caution in patients with a history of seizures, mania/hypomania, or untreated hypertension, which must be controlled before initiation.

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of Алвента (Venlafaxine) based on pharmacokinetic changes, pharmacodynamic risks, and formal prohibitions.

Interaction Classification	Documented Agents / Constraint
Formally Contraindicated	Monoamine Oxidase Inhibitors (MAOIs), Linezolid, and Intravenous Methylene Blue.
Mandatory Timing Rule	A 14-day washout period is required when switching from an MAOI to venlafaxine; a 7-day period is required when switching from venlafaxine to an MAOI.

Risk of Serotonin Syndrome: Co-administration with other Serotonergic Agents, including Triptans, SSRIs, SNRIs, Tramadol, and the herbal product St. John’s Wort, may officially increase the risk of Serotonin Syndrome. Concomitant use with Tryptophan supplements is not recommended.

Exposure-Modifying Interactions: Agents that inhibit the CYP3A4 enzyme (e.g., Ketoconazole) may increase the plasma concentration ( AUC and Cmax) of both venlafaxine and its active metabolite, O-desmethylvenlafaxine (ODV). Venlafaxine can also cause an increase in the plasma levels of co-administered drugs like Haloperidol and Metoprolol.

Bleeding Risk and CNS Effects: Co-administration with drugs that interfere with hemostasis, such as NSAIDs or Warfarin, is documented to increase the risk of Abnormal Bleeding. Official labeling advises patients to avoid alcohol due to the potential for enhanced central nervous system depressant effects. Furthermore, interactions may be amplified in individuals with hepatic or renal impairment due to reduced drug clearance.

Dual Neurotransmitter Reuptake Blockade

Алвента operates primarily by binding to and inhibiting two specific protein structures in the central nervous system: the Serotonin Transporter (SERT) and the Norepinephrine Transporter (NET). This interaction blocks the reuptake pump function, preventing the swift reabsorption of the neurotransmitters serotonin and norepinephrine back into the presynaptic neuron. This results in a higher, sustained concentration of both signaling molecules within the synaptic cleft.

Cascade Modulation and Neuroadaptation

The elevated and prolonged presence of these monoamines enhances signal transmission to the receiving nerve cells, which initiates a series of downstream physiological cascades. This sustained modulation of monoaminergic pathways triggers long-term neuroadaptive responses. This includes changes in the expression of neurotrophic factors (proteins supporting nerve cell function and structure). These mechanisms collectively shape the final profile of central nervous system activity through continuous modulation of specific neural circuits.

Administration Scope

Parameter	Instruction Details
Route of administration	Oral administration is the exclusive route for this medicine.
Dosing schedule	Extended-Release (ER) starting doses are typically 37.5 mg/day for four to seven days, followed by an increase to 75 mg/day. The maximum dose is generally 225 mg/day for most outpatient indications.
Timing in relation to meals	The medication is taken once daily with food, either in the morning or the evening, at approximately the same time each day.
Preparation requirements	Extended-Release capsules and tablets must be swallowed whole with fluid; they must not be divided, crushed, or chewed. The contents of ER capsules may be sprinkled on a spoonful of applesauce and swallowed immediately without chewing.
Age-group administration rules	The medicine is not indicated for use in pediatric patients. In older adults, caution is advised, and the lowest effective dose is utilized.
Missed-dose rules	If a dose is missed, it should not be doubled. The next scheduled dose should be taken at the usual time.
Special procedural conditions	The total daily dose requires reduction for patients with renal or hepatic impairment. For instance, a dose reduction of 25% to 50% or more is indicated for specific degrees of renal impairment.

Instruction Classifications (High-Level)

Classification	Detail
Administration method type	Oral
Frequency pattern	Once daily (for Extended-Release forms)
Information basis	Clinical and Pharmaceutical Guidelines
Use-context constraints	Must be taken with food; form integrity must be maintained; dosage must be adjusted in cases of specific organ impairment.

Resulting Procedural Structure

The standard instruction set defines the structured oral administration of this medicine. Treatment is initiated at a low dose and subsequently titrated in increments of up to 75 mg/day at intervals of not less than four days. The established usage pattern is long-term, and upon ending its use, the dose must be gradually reduced (tapered) over a period of at least one week or longer, rather than abruptly discontinued. This procedural structure standardizes the medicine's use from initiation to eventual cessation.

Research evidence / Overview of Studies for Алвента

The clinical evaluation of Алвента (venlafaxine) is based on a large volume of official research, including numerous Randomized Controlled Trials (RCTs), systematic reviews, and meta-analyses. These studies were used in research exploring how symptoms change over time across various conditions, and the evidence base reflects the research structure relied upon by regulators and scientific bodies.

Evidence Base for Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD)

The research for both MDD and GAD is supported by numerous RCTs and is described in multiple sources. For MDD, the evidence is drawn from a large number of short-term (e.g., 8 to 12 weeks) RCTs conducted in adult populations. These trials examined measurements of change in the overall severity of depressive symptoms. Study outcomes also included measurements related to achieving a specified level of symptom reduction and remission status. Findings describe the patterns of symptom measurements observed in the study populations during the acute treatment phase.

For GAD, controlled trials measured changes in anxiety severity, looking at both the mental component (worry) and outcomes related to physical discomfort (somatic symptoms). The research reports changes measured during the study period, contributing to the broader evidence landscape for GAD.

Research on Specialized Symptomatic Uses

Separate, often smaller, trials have explored the potential role of this medication in managing certain symptoms not directly related to mood or anxiety in all populations. This includes conditions like Chronic Neuropathic Pain, which was studied for pain intensity in specific patient groups, and Vasomotor Symptoms (hot flashes), which was evaluated in trials focused on outcomes monitoring physiological strain or stress.

What Research Gaps and Uncertainties Remain

Official reviews identify several areas where data remain insufficient or where the results apply only to the populations studied. While research provides insight into short-term changes, there is limited information for long-term outcomes regarding functional recovery over periods exceeding one or two years. Additionally, data for certain groups, such as children and adolescents, remain insufficient in the core RCTs. For specialized uses like chronic neuropathic pain, the findings were mixed across various studies, indicating that certainty remains low for a broad application.

Key Studies & References

1. Venlafaxine extended-release capsules in panic disorder
2. Effectiveness of Long-Term Versus Short-Term Treatment of Generalized Anxiety Disorder With Venlafaxine XR (ClinicalTrials.gov ID NCT00183274)

Common questions about Алвента (FAQ)

---

Q: Does Алвента (Alventa) help with anxiety?

Studies and official information indicate that Алвента (Alventa), containing the active substance venlafaxine, is approved for treating generalized anxiety disorder (GAD) and social anxiety disorder (SAD), in addition to major depressive episodes. Therefore, regulatory documents confirm its use for managing certain types of anxiety.

---

Q: How long does it take for Алвента (Alventa) to start working?

Regulatory information indicates that it may take several weeks for the full therapeutic effect of Алвента to be felt. While some effects may be noticed earlier, the full benefit for depression and anxiety may not be evident until a few weeks after starting the treatment, according to official product information.

---

Q: Can I stop taking Алвента (Alventa) on my own?

Official regulatory documents indicate that suddenly stopping treatment with Алвента or reducing the dose without medical supervision is not recommended. Abrupt changes carry a risk of withdrawal symptoms, which can be bothersome or serious. Changes to the treatment schedule are typically managed gradually under the guidance of a healthcare professional.

---

Q: Is it safe to drink alcohol while taking Алвента (Alventa)?

According to the official product information, the use of alcohol is not recommended while taking Алвента. Combining alcohol with this medicine can potentially increase the risk of central nervous system side effects, such as drowsiness or dizziness, and may interfere with the condition being treated.

---

Q: What should I do if I miss a dose of Алвента (Alventa)?

Official product information provides specific instructions for managing a missed dose, which typically involves taking it when remembered or skipping it if the next dose is due soon. For personalized guidance on managing a missed dose, refer to the full 'How to use' section or consult your healthcare provider. It is important never to take more than the prescribed amount at any single time.

---

Q: What is the active ingredient in Алвента (Alventa)?

The active substance in Алвента is venlafaxine, which belongs to a class of medicines called serotonin and norepinephrine reuptake inhibitors (SNRIs). This ingredient works in the brain to help restore the balance of certain natural substances, known as neurotransmitters, like serotonin and norepinephrine.

---

Q: Can Алвента (Alventa) cause weight gain?

Official product documents list changes in weight as a possible side effect of taking Алвента, meaning both weight gain and weight loss have been reported in clinical studies. This is listed under possible undesirable effects. If significant or unexpected weight changes occur, it is recommended to consult a healthcare provider.

The storage and disposal of Алвента (Venlafaxine prolonged-release capsules) must adhere strictly to official regulatory requirements to maintain product stability and ensure public safety.

Storage Requirements

Condition	Official Regulatory Requirement
Temperature	Store at controlled room temperature, typically 20 C to 25 C.
Protection	Keep the medicine in its closed, original container and store it away from heat, moisture, and direct light.
Prohibited	The product must be kept from freezing.

Disposal and Safety

All medication must be stored out of the sight and reach of children. Outdated or unused capsules should not be flushed down a toilet or thrown into household trash. Individuals must consult a healthcare professional or pharmacist for instructions on how to properly dispose of the unused product in accordance with local pharmaceutical waste regulations.